Voigt et al. have recently demonstrated that inhibition of IL‐22 production through IL‐1R antagonist anakinra can reduce tumor burden in a transplant tumor model and identified Th22 cells as a primary source of IL‐22 in breast cancer. Here, IL22 is linked to neoplasm.